CMRX Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals PLC has a net margin of -40270.18% compared to Chimerix's net margin of 17.56%. Chimerix's return on equity of -56.65% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.12%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $192.72 which suggests that it could grow by 75.01%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Chimerix, analysts believe Jazz Pharmaceuticals PLC is more attractive than Chimerix.

Chimerix has a beta of -0.176, which suggesting that the stock is 117.551% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.096%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Chimerix's net income of -$23M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Chimerix's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 12.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 1.74x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -40270.18% compared to Chimerix's net margin of -117.16%. Chimerix's return on equity of -56.65% beat Moderna's return on equity of -29.09%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.12%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 95.16%. Given that Moderna has higher upside potential than Chimerix, analysts believe Moderna is more attractive than Chimerix.

Chimerix has a beta of -0.176, which suggesting that the stock is 117.551% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Moderna quarterly revenues of $956M. Chimerix's net income of -$23M is higher than Moderna's net income of -$1.1B. Notably, Chimerix's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 3.23x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -40270.18% compared to Chimerix's net margin of --. Chimerix's return on equity of -56.65% beat Omeros's return on equity of --.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.12%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 453.85%. Given that Omeros has higher upside potential than Chimerix, analysts believe Omeros is more attractive than Chimerix.

Chimerix has a beta of -0.176, which suggesting that the stock is 117.551% less volatile than S&P 500. In comparison Omeros has a beta of 2.352, suggesting its more volatile than the S&P 500 by 135.194%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are larger than Omeros quarterly revenues of --. Chimerix's net income of -$23M is higher than Omeros's net income of -$32.2M. Notably, Chimerix's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -40270.18% compared to Chimerix's net margin of 24.22%. Chimerix's return on equity of -56.65% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.12%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $904.00 which suggests that it could grow by 56.75%. Given that Regeneron Pharmaceuticals has higher upside potential than Chimerix, analysts believe Regeneron Pharmaceuticals is more attractive than Chimerix.

Chimerix has a beta of -0.176, which suggesting that the stock is 117.551% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Chimerix pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Chimerix's net income of -$23M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Chimerix's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 4.67x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.